

Table 3: Sustained Virological Response (SVR) to antiviral treatment and chronic hepatitis C (CHC) patients characteristics.

	SVR		
	No 49.6 (37.5, 60.6) N (%)	Yes 37.3 (29.2, 47.2) N (%)	
Age [years; Median (IQR*)]			<0.001
Gender			p-value 0.263
<i>Male</i>	225 (46.6)	258 (53.4)	
<i>Female</i>	160 (50.6)	156 (49.4)	
Ethnicity			0.755
<i>Greek</i>	267 (46.8)	304 (53.2)	
<i>Other</i>	78 (48.1)	84 (51.9)	
Alcohol abuse			0.541
<i>Yes</i>	65(49.6)	66(50.4)	
<i>No</i>	273(46.7)	312(53.3)	
Possible source of infection			<0.001
<i>Intravenous drug use</i>	69 (31.2)	152 (68.8)	
<i>Transfusion</i>	109 (58.3)	78 (41.7)	
<i>Other</i>	75 (53.2)	66 (46.8)	
<i>Unknown</i>	132 (52.8)	118 (47.2)	
Duration of infection (years)			<0.001
<i><10</i>	35 (26.7)	96 (73.3)	
<i>10-19.9</i>	74 (47.1)	83 (52.9)	
<i>20+</i>	115 (59.3)	79 (40.7)	
Genotype			<0.001
<i>1</i>	221 (62.4)	133 (37.6)	
<i>2</i>	25 (35.2)	46 (64.8)	
<i>3</i>	73 (27.1)	196 (72.9)	
<i>4</i>	66 (62.9)	39 (37.1)	
HCV-treatment naive	113 (68.9)	51 (31.1)	<0.001
Type of PEG-IFNα + RIB			0.814
<i>PEG-IFNα-2a + RIB</i>	167 (47.7)	183 (52.3)	
<i>PEG-IFNα-2b + RIB</i>	218 (48.6)	231 (51.4)	
Cirrhosis at baseline	63 (74.1)	22 (25.9)	<0.001
Baseline APRI score (n=782)			0.003
<i><0.5</i>	108 (41.4)	153 (58.6)	
<i>0.5-0.99</i>	83 (42.1)	114 (57.9)	
<i>1+</i>	110 (56.1)	86 (43.9)	
Normal ALT[†] (IU/L; n=828)	214 (46.6)	245 (53.4)	0.655
Normal AST[‡] (IU/L; n=823)	229 (43.5)	297 (56.5)	0.013
TBIL[§]<1.5 (mg/dL; n=687)	241 (44.6)	299 (55.4)	0.110
PLT[¶]>150000 (/mm³; n=794)	214 (42.3)	292 (57.7)	0.001

[†]Alanine Aminotransferase, [‡]Aspartate Aminotransferase, [§]Total Bilirubin, [¶]Platelets, ^{**}N=799 for those with available laboratory or clinical information at 6 months after the end of treatment, * Interquartile Range.